Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Glide Pharmaceutical Technologies
Glide Pharmaceutical Technologies
Activities:
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Glide Technologies collaborates with Cilian to develop flu vaccine
Will develop a solid dose formulation of CiFlu recombinant influenza vaccine
Research & Development
Glide skin delivery and human factor studies highlight ease-of-use of solid dose injection system
Company plans to evaluate octreotide product in a clinical bioequivalence study in Q4 2015
Manufacturing
AMRI to manufacture clinical trial product for Glide Technologies
Will install the clinical production line developed by Glide into its newly acquired GMP facility in Glasgow
Drug Delivery
Glide Pharma to work with Nypro Healthcare for scale-up of delivery device
Glide SDI injects drugs and vaccines in a solid dosage form without requiring a needle
Manufacturing
Glide Pharma to work with Nypro Healthcare for scale up of solid dose delivery device
The Glide SDI injects drugs and vaccines in a solid dosage form without the need for a needle
Drug Delivery
Glide Pharma raises £14m for scale up of manufacturing processes
For proprietary Glide-SDI solid dose injector system
Drug Delivery
Glide Pharma wins
Existing investors Hygea VCT and Oxford Technology VCT have made further investment in pharmaceutical firm Glide Pharma as part of a
Subscribe now